Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia (WM): Real‑world evidence from the United States
This retrospective observational study evaluated real‑world treatment utilization, sequencing patterns, and healthcare resource utilization (HCRU) among patients with Waldenström macroglobulinemia (WM) in the United States.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia